Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2014-03-03

Original market date: See footnote 1

2014-03-03

Product name:

ARANESP

Description:

HSA-FREE. 30 MCG/0.3 ML SINGLE-USE PREFILLED SYRINGES (SINGLEJECT)

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02392348

Product Monograph/Veterinary Labelling:

Date: 2018-05-24 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

AMGEN CANADA INC
300 6775 Financial Drive
Mississauga
Ontario
Canada L5N 0A4

Class:

Human

Dosage form(s):

Solution

Route(s) of administration:

Intravenous ,  Subcutaneous

Number of active ingredient(s):

1

Schedule(s):

Schedule D ,  Prescription

 

American Hospital Formulary Service (AHFS): See footnote 3

20:16.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

B03XA02 DARBEPOETIN ALFA

Active ingredient group (AIG) number:See footnote5

0148081005

List of active ingredient(s)
Active ingredient(s) See footnote8 Strength
DARBEPOETIN ALFA 100 MCG / ML
Version 4.0.3

"Page details"

Date modified: